OTCPK:QNTA

Stock Analysis Report

Executive Summary

Quanta, Inc., an applied science company, focuses on enhancing energy levels in plant matter to increase performance within the human body.

Snowflake

Fundamentals

Weak fundamentals or lack of information.

Share Price & News

How has Quanta's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-16.7%

QNTA

1.4%

US Healthcare Services

1.8%

US Market


1 Year Return

n/a

QNTA

15.6%

US Healthcare Services

7.3%

US Market

Return vs Industry: Insufficient data to determine how QNTA performed against the US Healthcare Services industry.

Return vs Market: Insufficient data to determine how QNTA performed against the US Market.


Shareholder returns

QNTAIndustryMarket
7 Day-16.7%1.4%1.8%
30 Day-84.9%-0.9%-0.7%
90 Dayn/a-5.3%0.06%
1 Yearn/a15.8%15.6%9.7%7.3%
3 Yearn/a57.1%56.6%46.3%36.9%
5 Yearn/a49.8%48.7%64.5%46.5%

Price Volatility Vs. Market

How volatile is Quanta's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Quanta undervalued compared to its fair value and its price relative to the market?

69.61x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate QNTA's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate QNTA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: QNTA is unprofitable, so we can't compare its PE Ratio to the Healthcare Services industry average.

PE vs Market: QNTA is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate QNTA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: QNTA is overvalued based on its PB Ratio (69.6x) compared to the US Healthcare Services industry average (3.7x).


Next Steps

Future Growth

How is Quanta forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

27.7%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Quanta has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of QNTA’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Quanta's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Quanta performed over the past 5 years?

-206.9%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: Unable to establish if QNTA's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.

Accelerating Growth: Unable to compare QNTA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: QNTA is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (3.3%).


Return on Equity

High ROE: QNTA has a negative Return on Equity (-2051.12%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: QNTA is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: QNTA is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Quanta's financial position?


Financial Position Analysis

Short Term Liabilities: QNTA's short term assets ($71.1K) do not cover its short term liabilities ($307.7K)

Long Term Liabilities: QNTA's short term assets (71.1K) do not cover its long term liabilities (355.9K)


Debt to Equity History and Analysis

Debt Level: QNTA's debt to equity ratio (83.7%) is considered high

Reducing Debt: Insufficient data to determine if QNTA's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: QNTA has a high level of physical assets or inventory.

Debt Coverage by Assets: QNTA's debt is not covered by short term assets (assets are 0.5x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: QNTA has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: QNTA has less than a year of cash runway if free cash flow continues to reduce at historical rates of -57.5% each year


Next Steps

Dividend

What is Quanta's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.7%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate QNTA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate QNTA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if QNTA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if QNTA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of QNTA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Quanta's salary, the management and board of directors tenure and is there insider trading?


CEO

Eric Rice (42yo)

1.3yrs

Tenure

0

Mr. Eric Rice is the Founder of Quanta Inc. in 2016 and serves as its Chief Executive Officer since June 6, 2018 and its Chairman and Chief Financial Officer. Prior to founding Quanta in 2016, Mr. Rice fou ...


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Eric Rice (42yo)

    Founder

    • Tenure: 1.3yrs
  • Jeffrey Doiron (46yo)

    President & COO

    • Tenure: 0yrs
  • Arthur Mikaelian

    Chief Science Officer & Director

    • Tenure: 0.3yrs

Board Members

  • Eric Rice (42yo)

    Founder

    • Tenure: 1.3yrs
  • Arthur Mikaelian

    Chief Science Officer & Director

    • Tenure: 0.3yrs
  • Annabelle Manalo

    Member of Advisory Board

    • Tenure: 0.3yrs

Company Information

Quanta, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Quanta, Inc.
  • Ticker: QNTA
  • Exchange: OTCPK
  • Founded: 2016
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: US$13.389m
  • Shares outstanding: 44.65m
  • Website: https://null

Number of Employees


Location

  • Quanta, Inc.
  • 3606 West Magnolia Boulevard
  • Burbank
  • California
  • 91505
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
QNTAOTCPK (Pink Sheets LLC)YesNew Common StockUSUSDJun 2018

Biography

Quanta, Inc., an applied science company, focuses on enhancing energy levels in plant matter to increase performance within the human body. Its proprietary technology uses quantum mechanics to increase bio ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/18 00:23
End of Day Share Price2019/10/17 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.